Liraglutide, a glucagon-like peptide-1 (GLP-1) analog that binds to and activates GLP-1R, is primarily used to treat type 2 diabetes and obesity (9, 10). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.